Articles
06-Feb-2026
“An ounce of prevention is worth a pound of cure.” Benjamin Franklin’s maxim may predate modern medicine, yet its logic underpins the realities of pharmaceutical manufacturing today. When a single interruption can destabilise controlled systems, jeopardise batch integrity or delay time-critical medicines, preventing disruption is as important as resolving it. Here, Andrew Keith, division director of load bank manufacturer Power Prove, examines how robust backup power testing helps reduce unplanned downtime in pharmaceutical operations.
~ How load bank testing prevents downtime in pharmaceutical manufacturing ~ “An ounce of prevention is worth a pound of cure.” Benjamin Franklin’s maxim may predate modern medicine, yet its logic underpins the realities of pharmaceutical manufacturing today.…
~ How load bank testing prevents downtime in pharmaceutical manufacturing ~ “An ounce of prevention is worth a pound of cure.” Benjamin Franklin’s maxim may predate modern medicine, yet its logic underpins the realities of pharmaceutical manufacturing today.…
Pharmacovigilance (PV) teams are facing sustained pressure from rising ICSR volumes, expanding intake channels (partners, call centres, patient programs, digital touchpoints), tighter regulatory timelines, and higher expectations for inspection readiness. Many organisations, however, still run PV operations through fragmented mailboxes, manual triage queues, and spreadsheet-heavy reconciliation. The most effective modernisation approach is not “adding AI everywhere,” but redesigning PV workflows so repeatable work is orchestrated consistently, exceptions are handled early, and medical judgement remains explicit and auditable.
Modernizing Pharmacovigilance Operations: Practical Automation Patterns for Case Intake, Triage, and Signal Workflows Pharmacovigilance (PV) teams are facing a sustain…
Modernizing Pharmacovigilance Operations: Practical Automation Patterns for Case Intake, Triage, and Signal Workflows Pharmacovigilance (PV) teams are facing a sustain…
Explore how AI is transforming clinical trials—from study design and data management to monitoring, compliance, and faster trial outcomes
AI in clinical trials is addressing the challenges of escalating data complexity and accelerated timelines. AI in clinical trials is being used to handle increasing complexity, larger volumes of data, and shorter development timelines. It enhances not only operational efficiency but also the underlying approach to study design and management, facilitating faster and more reliable insights for strategic decisions. Introduction: Clinical Research at an Inflection Point Clinical trials remain the definitive mechanism for validating the safety, efficacy, and real-world applicability of new therapies and medical devices. Yet despite decades of methodological r…
AI in clinical trials is addressing the challenges of escalating data complexity and accelerated timelines. AI in clinical trials is being used to handle increasing complexity, larger volumes of data, and shorter development timelines. It enhances not only operational efficiency but also the underlying approach to study design and management, facilitating faster and more reliable insights for strategic decisions. Introduction: Clinical Research at an Inflection Point Clinical trials remain the definitive mechanism for validating the safety, efficacy, and real-world applicability of new therapies and medical devices. Yet despite decades of methodological r…
The global biomarkers market is at the forefront of healthcare’s shift toward precision, data-driven medicine. Valued at USD 85.9 billion in 2025 and projected to reach USD 244.8 billion by 2034 at a CAGR of 12.3%.
The landscape of modern healthcare is undergoing a seismic shift, moving away from "one-size-fits-all" treatments toward a highly tailored, data-driven approach. At the heart of this transformation is the global biomarkers market. Valued at USD 85.9 billion in 2025, the sector is projected to surge to an astonishing USD 244.8 billion by 2034. This trajectory, representing a compound annual growth rate (CAGR) of 12.3%, underscores a fundamental change in how we diagnose, monitor, and treat chronic diseases. The Catalysts of Growth: Why Now? The explosive expansion of the biomarker…
The landscape of modern healthcare is undergoing a seismic shift, moving away from "one-size-fits-all" treatments toward a highly tailored, data-driven approach. At the heart of this transformation is the global biomarkers market. Valued at USD 85.9 billion in 2025, the sector is projected to surge to an astonishing USD 244.8 billion by 2034. This trajectory, representing a compound annual growth rate (CAGR) of 12.3%, underscores a fundamental change in how we diagnose, monitor, and treat chronic diseases. The Catalysts of Growth: Why Now? The explosive expansion of the biomarker…
The use of AI in pharmaceutical development is becoming widespread, but the rulebook is still being written.
The use of AI in pharmaceutical development is becoming widespread, but the rulebook is still being written. McKinsey reports that 71% of businesses across various industries now use generative AI, with life sciences sitting among the fastest adopters. However, only 53% actively mitigate AI risks. This gap now leads to unease, as pharmaceutical companies deploy autonomous systems across R&D and manufacturing while simultaneously building their governance frameworks. The conversation has moved on from whether AI belongs in drug discovery or production lines. The big question is how those businesses secure innovation without restricting the impact that makes AI so valuable. Operati…
The use of AI in pharmaceutical development is becoming widespread, but the rulebook is still being written. McKinsey reports that 71% of businesses across various industries now use generative AI, with life sciences sitting among the fastest adopters. However, only 53% actively mitigate AI risks. This gap now leads to unease, as pharmaceutical companies deploy autonomous systems across R&D and manufacturing while simultaneously building their governance frameworks. The conversation has moved on from whether AI belongs in drug discovery or production lines. The big question is how those businesses secure innovation without restricting the impact that makes AI so valuable. Operati…
A team led by researchers at Chalmers University of Technology, Sweden, has succeeded in identifying biomarkers for Parkinson’s disease in its earliest stages, before extensive brain damage has occurred. The biological processes leave measurable traces in the blood, but only for a limited period. The discovery thus reveals a window of opportunity that could be crucial for future treatment, but also for early diagnosis via blood tests, which could begin to be tested in healthcare within five years.
Parkinson’s is an endemic disease with over 10 million people affected globally. As the world’s population grows older, this number is expected to more than double by 2050. At present, there is neither an effective cure nor an established screening method for detecting this chronic neurological d…
Parkinson’s is an endemic disease with over 10 million people affected globally. As the world’s population grows older, this number is expected to more than double by 2050. At present, there is neither an effective cure nor an established screening method for detecting this chronic neurological d…
24-Jan-2026
Explore the top EDC platforms for clinical trials in 2026. Features, strengths, limitations, and how to choose the right platform for your study.
Choosing the right EDC (electronic data capture) platform is critical for sponsors, CROs, and clinical operations teams running modern trials. In 2026, clinical trial software solutions have become increasingly sophisticated, ranging from enterprise suites to lean, budget-friendly tools. These clinical trial data capture software systems replace legacy tools with secure, centralized, and modern systems, ensuring 21 CFR Part 11 audit trails, encryption, and compliance with ICH-GCP guidelines. EDC systems are central to modern clinical trials, enhancing data accuracy while enabling real-time monitoring, faster database locks, and streamlined wor…
Choosing the right EDC (electronic data capture) platform is critical for sponsors, CROs, and clinical operations teams running modern trials. In 2026, clinical trial software solutions have become increasingly sophisticated, ranging from enterprise suites to lean, budget-friendly tools. These clinical trial data capture software systems replace legacy tools with secure, centralized, and modern systems, ensuring 21 CFR Part 11 audit trails, encryption, and compliance with ICH-GCP guidelines. EDC systems are central to modern clinical trials, enhancing data accuracy while enabling real-time monitoring, faster database locks, and streamlined wor…
Discover the predicted 2026 global rankings of China's leading pharmaceutical exporters, from innovation giants like Jiangsu Hengrui to emerging players. Explore trends, deals, and forecasts shaping the $177B export market.
In 2026, China's pharmaceutical export sector is poised for significant expansion, building on 2025's record-breaking out-licensing deals and a surge in innovative therapies. As the world's second-largest developer of new medicines, China is transitioning from a generics powerhouse to a global innovation leader, with exports projected to hit $176.92 billion—a substantial rise from $126.39 billion in 2024. This article, prepared for publication on www.pharmiweb.com, draws on authoritative sources like Statista, IQVIA, and the Pharma 50 rankings to forecast the latest glob…
In 2026, China's pharmaceutical export sector is poised for significant expansion, building on 2025's record-breaking out-licensing deals and a surge in innovative therapies. As the world's second-largest developer of new medicines, China is transitioning from a generics powerhouse to a global innovation leader, with exports projected to hit $176.92 billion—a substantial rise from $126.39 billion in 2024. This article, prepared for publication on www.pharmiweb.com, draws on authoritative sources like Statista, IQVIA, and the Pharma 50 rankings to forecast the latest glob…
Anti-aging and longevity are expanding beyond beauty into an industry driven by biomarkers like blood sugar, inflammation, sleep, muscle, and biological age. The key question is whether longevity is healthcare or lifestyle, shaping regulation, evidence, pricing, and consumers. Healthcare focuses on measurable interventions to reduce disease risk, while lifestyle emphasizes daily habits supported by nutraceuticals, wearables, and digital coaching. Ultimately, the market grows fastest in the middle ground, where trust and sustainable routines matter most.
The desire to stay young is almost instinctive. Yet in recent years, that desire has evolved beyond simple beauty or wellness, transforming into an entire industry known as longevity. In the past, youthful appearance was often associated wit…
The desire to stay young is almost instinctive. Yet in recent years, that desire has evolved beyond simple beauty or wellness, transforming into an entire industry known as longevity. In the past, youthful appearance was often associated wit…
21-Jan-2026
Clinical trial sites deal with many small challenges during daily work managing patient visits, paperwork and timelines can be stressful at times teams also face issues like staff shortages and sudden protocol changes; this article explains the common problems trial sites face and how they affect day to day operations.
When we think of a clinical trial we often imagine the global breakthroughs the headlines announcing a new cure or a revolutionary vaccine however the true work happens in the trenches at the clinical trial sites where research becomes real life care. For those beginning their journey with a clinical research course in India the curriculum often highlights the ideal protocol but as any seasoned professional will tell you the day to day reality at a research site is a delicate…
When we think of a clinical trial we often imagine the global breakthroughs the headlines announcing a new cure or a revolutionary vaccine however the true work happens in the trenches at the clinical trial sites where research becomes real life care. For those beginning their journey with a clinical research course in India the curriculum often highlights the ideal protocol but as any seasoned professional will tell you the day to day reality at a research site is a delicate…
Hello, I am Gautami Gangadiya, an SEO executive at BotPhonic, and I am passionate about driving digital growth by optimizing presence with strategic SEO initiatives. Let's elevate your brand together!
Introduction The rapid growth of technology-driven customer service makes AI Call Centres among the essentials of modern business today. With the aid of a virtual AI Call Assistant, an organization can do almost all tasks of AI Phone Call concerning customer service and essentially high-quality. An application in a virtual AI Receptionist helps in reducing costs, speeding processes, and allowing personnel to attend queries only an actual human figure can answer. In other words, intelligent systems integrated with automation revolutionizes how organizations go about achieving that cost-effec…
Introduction The rapid growth of technology-driven customer service makes AI Call Centres among the essentials of modern business today. With the aid of a virtual AI Call Assistant, an organization can do almost all tasks of AI Phone Call concerning customer service and essentially high-quality. An application in a virtual AI Receptionist helps in reducing costs, speeding processes, and allowing personnel to attend queries only an actual human figure can answer. In other words, intelligent systems integrated with automation revolutionizes how organizations go about achieving that cost-effec…
In high-volume manufacturing, the margin for error is non-existent. When producing components for medical disposable products, industrial machinery or performance apparel. The physical properties of a polymer must remain identical from the first pound to the ten-thousandth. Any fluctuation in tensile strength or material performance can lead to product failure or costly production downtime.
Achieving this level of reliability requires more than just heavy machinery; it demands a scientific approach to polymer chemistry and a disciplined manufacturing process. The Foundation of Batch Consistency Consistency begins with the precision of the formulation. Even slight variations in the quality of raw materials or the sequence of addition can alter the final compound’s behaviour. Fulflex offers…
Achieving this level of reliability requires more than just heavy machinery; it demands a scientific approach to polymer chemistry and a disciplined manufacturing process. The Foundation of Batch Consistency Consistency begins with the precision of the formulation. Even slight variations in the quality of raw materials or the sequence of addition can alter the final compound’s behaviour. Fulflex offers…
Chinese ADC Breakthroughs Gain Global Momentum: Hope for Breast Cancer Patients Worldwide
Meta Description:
Discover how China's innovative ADCs, including sac-TMT and Disitamab Vedotin, are advancing globally for breast cancer treatment. Explore targets, mechanisms, and clinical data driving precision oncology worldwide.
Picture this: a breast cancer diagnosis that once meant endless cycles of harsh chemotherapy, now shifting toward smarter, more targeted therapies that attack cancer cells while sparing healthy ones. For millions of patients globally, this isn't just hope—it's becoming reality through innovative antibody-drug conjugates (ADCs) developed in China and rapidly expanding to international stages. These precision medicines are crossing borders, entering multinational trials, a…
Picture this: a breast cancer diagnosis that once meant endless cycles of harsh chemotherapy, now shifting toward smarter, more targeted therapies that attack cancer cells while sparing healthy ones. For millions of patients globally, this isn't just hope—it's becoming reality through innovative antibody-drug conjugates (ADCs) developed in China and rapidly expanding to international stages. These precision medicines are crossing borders, entering multinational trials, a…
In the race to bring new biologics to market, development teams are constantly balancing speed, quality, and regulatory expectations. Yet one factor often determines long-term success more than any other: the strength of the data generated in the earliest phases of cell line development.
In the race to bring new biologics to market, development teams are constantly balancing speed, quality, and regulatory expectations. Yet one factor often determines long-term success more than any other: the strength of the data generated in the earliest phases of cell line development. Meticulous records of clonality, phenotypic stability, and quality control do more than simply satisfy regulators. They set an established groundwork for reproducible yield and effective tech transfer from early-stage deve…
In the race to bring new biologics to market, development teams are constantly balancing speed, quality, and regulatory expectations. Yet one factor often determines long-term success more than any other: the strength of the data generated in the earliest phases of cell line development. Meticulous records of clonality, phenotypic stability, and quality control do more than simply satisfy regulators. They set an established groundwork for reproducible yield and effective tech transfer from early-stage deve…
By Vibhor Gupta, founder & CEO of Pangaea Data -
As 2026 begins, the conversation around AI in healthcare feels markedly different from this time last year. Not because the technology itself has changed, but because expectations have. Across health systems, life sciences and R&D departments, there’s been a profound shift away from experimentation for its own sake towards accountable, transparent and reliable AI that demonstrates ROI within real care pathways, under real-world conditions.
As 2026 begins, the conversation around AI in healthcare feels markedly different from this time last year. Not because the technology itself has changed, but because expectations have. Across health systems, life sciences and R&D departments, there’s been a profound shift away from experimentation…
As 2026 begins, the conversation around AI in healthcare feels markedly different from this time last year. Not because the technology itself has changed, but because expectations have. Across health systems, life sciences and R&D departments, there’s been a profound shift away from experimentation…
Aston University and Midlands-based company PFE Medical are teaming up to create biodegradable gloves made from food waste for use in the NHS.
Knowledge Transfer Partnership between Aston University and PFE Medical to develop a biodegradable clinical glove from food waste The gloves will provide a low-cost, convenient and sustainable alternative to the 1.4bn disposable gloves used in the NHS each year The innovation will reduce clinical waste and costs and help the NHS reach its net zero goals. Aston University and Midlands-based company PFE Medical are teaming up to create biodegradable gloves made from food waste for use in the NHS. They will offer a low-cost, convenient alternative to disposable gloves without compromising patient safety. More than 1.4bn disposable gloves are used by t…
Knowledge Transfer Partnership between Aston University and PFE Medical to develop a biodegradable clinical glove from food waste The gloves will provide a low-cost, convenient and sustainable alternative to the 1.4bn disposable gloves used in the NHS each year The innovation will reduce clinical waste and costs and help the NHS reach its net zero goals. Aston University and Midlands-based company PFE Medical are teaming up to create biodegradable gloves made from food waste for use in the NHS. They will offer a low-cost, convenient alternative to disposable gloves without compromising patient safety. More than 1.4bn disposable gloves are used by t…
PD-1 inhibitors (e.g., toripalimab, tislelizumab) from China are transforming cancer treatment worldwide, with approvals in the US and Europe for lung cancer, esophageal cancer, and more. This shift brings affordable, effective options to patients globally. From my view as editor at Hong Kong DengYue Medicine (dengyuemed.com), it's driven by pursuit of excellence, innovation, quality, integrity, and social responsibility for sustainable health equity. These advancements resonate deeply with those affected by cancer—sharing your stories or hopes?
As someone who's followed the evolution of cancer treatments closely—both personally, having supported loved ones through their battles, and professionally in the pharmaceutical space—I've been inspired by the quiet revolution happening with Chinese…
As someone who's followed the evolution of cancer treatments closely—both personally, having supported loved ones through their battles, and professionally in the pharmaceutical space—I've been inspired by the quiet revolution happening with Chinese…
Technology is changing how clinical trials are planned and carried out today simple digital tools help researchers collect data faster and reduce mistakes. Online systems also make it easier to track patient safety and study progress because of this trials can run more smoothly and reach results in less time while keeping patient care important.
The way we discover and test new medicines is undergoing a massive transformation for decades the process of bringing a life saving drug to the public was a slow, paper heavy journey that required patients to live near major city hospitals. However as we move further into 2026 technology has become the heartbeat of medical progress for anyone looking to start a career in this field, the first step is often enrolling in a clinical research course in…
The way we discover and test new medicines is undergoing a massive transformation for decades the process of bringing a life saving drug to the public was a slow, paper heavy journey that required patients to live near major city hospitals. However as we move further into 2026 technology has become the heartbeat of medical progress for anyone looking to start a career in this field, the first step is often enrolling in a clinical research course in…
Bioprinting is transforming pharma and biotech by enabling realistic human tissue models, accelerating drug discovery, and supporting personalised medicine. As adoption grows, it is creating new jobs across research, engineering, data science, quality, manufacturing, and commercial strategy.
Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and biotechnology industries think about drug development, regenerative medicine, and personalised healthcare. For professionals exploring future focused careers, bioprinting represents one of the most exciting intersections of biology, engineering, and digital innovation. Below, we explore what bioprinting is, why it is so important to pharma and biotech, and the key job roles it is expe…
Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and biotechnology industries think about drug development, regenerative medicine, and personalised healthcare. For professionals exploring future focused careers, bioprinting represents one of the most exciting intersections of biology, engineering, and digital innovation. Below, we explore what bioprinting is, why it is so important to pharma and biotech, and the key job roles it is expe…
Learn what a clinical trial protocol is, why it matters, and how it guides study design, compliance, and execution in clinical research.
A clinical trial protocol is the foundation of clinical research, detailing objectives, study design, eligibility, safety oversight, and data analysis. Its structure ensures consistency and credibility, guiding investigators while protecting participants and maintaining scientific rigor. With digital solutions, eProtocols and AI are modernizing protocols in clinical trials, making processes more adaptive and reducing inefficiencies. Introduction Every clinical trial depends on a detailed plan that outlines how the study will be run, how participants will be safeguarded, and how results will be measured. This plan, called a clini…
A clinical trial protocol is the foundation of clinical research, detailing objectives, study design, eligibility, safety oversight, and data analysis. Its structure ensures consistency and credibility, guiding investigators while protecting participants and maintaining scientific rigor. With digital solutions, eProtocols and AI are modernizing protocols in clinical trials, making processes more adaptive and reducing inefficiencies. Introduction Every clinical trial depends on a detailed plan that outlines how the study will be run, how participants will be safeguarded, and how results will be measured. This plan, called a clini…
